1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

aRigen strikes first deal for novel anti-MRSA agent

 
• By Ian Haydock

Green Cross Corp has acquired rights in South Korea to aRigen Pharmaceuticals' lotilibcin (WAP-8294A2), in what is the first licensing deal for the novel anti-MRSA agent.

Green Cross Corp has acquired rights in South Korea to aRigen Pharmaceuticals' lotilibcin (WAP-8294A2), in what is the first licensing deal for the novel anti-MRSA agent.

The agreement gives Green Cross exclusive development and commercialisation rights in its home market in return for undisclosed upfront, milestone...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

Moderna’s Spikevax Wins Pediatric Approval, But With Narrower Label

 
• By Alaric DeArment

The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 
• By Dexter Jie Yan

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By Joseph Haas

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

Moderna Posts Phase III Efficacy Data For Flu Vaccine

 
• By Joseph Haas

With positive relative efficacy data for its mRNA seasonal flu shot, Moderna hopes to file mRNA-1010 for US approval and refile a COVID-19/flu combo shot that it withdrew in May.

More from Therapeutic Category

PureTech Ponders Way Forward As CEO Exits

 
• By Kevin Grogan

Bharatt Chowrira departs days after firm’s chair stepped down.

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 
• By Anju Ghangurde

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By Joseph Haas

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.